

PRESS RELEASE

DOSIsoft Contributing Partner of the European Thera4Care project - Theranostics Ecosystem For Personalized Care

DOSIsoft, leading provider of patient-specific imaging and dosimetry software solutions for radiation oncology and nuclear medicine, is proud to be part of the EU-funded Thera4care Project - a public-private initiative aiming to revolutionize precision oncology and establish Europe as a global leader in Theranostics, a cutting-edge approach combining diagnostics with targeted therapies to enable personalized treatments.

Contributing with its own R&D and granted 1,6 million€ of EU funding, **DOSIsoft will focus its efforts on the further development of dosimetry software**, sharing the vision that personalized dosimetry becomes a standard clinical practice.

Thera4care: Development and proof of principle of new clinical applications of theranostics solutions

Scheduled for 5 years and composed of 9 workpackage (WP), Thera4care brings **together 29 partners** from well-established European academic centers, research organizations, healthcare providers, SMEs, strong industry stakeholders and patient advocacy groups - **a unique consortium with multidisciplinary knowledge** - capable to develop and translate new radiotheranostic concepts, improve patient benefits and broaden access throughout Europe. Simultaneously, Thera4care is committed to **developing standardized and scalable dosimetry**, quantification, therapy-selection, and timely supply methodologies to **ensure precise treatment and optimize patient outcomes**.

Currently, radionuclide-based therapies are limited to a few specialized centers with the need to increase clinical treatment capacities, and to widen the arsenal of radiotheranostics. Thera4care has the ambition to expand understanding of dosimetry, with focus on ¹⁷⁷Lu-PSMA treatment, establish a robust methodological foundation for alpha-radiopharmaceutical dosimetry, and advance the clinical routinary application of radiotheranostics.

DOSIsoft: a dedicated involvement in “Dosimetry software development”

Perfectly sharing the Thera4Care’s vision, DOSIsoft plays a key role in **WP7 dedicated to “Dosimetry” studies**, especially contributing to one of the project’s overarching objectives: **“enhancing clinical outcomes through AI-based imaging and personalized dosing protocols”**.

By bringing its more than 20 years of software technological prowess and strong dosimetry expertise, **DOSIsoft is assigned to the specific task (WP7.8) - “Dosimetry software development” - to advance novel dosimetric concepts & improved imaging equipment**. The high-level clinical results are expected to provide standard protocols for imaging, simple and automatic dosimetry as well as dose adjustment ability:

- Enhanced dosimetry software for wider clinical use
- Support for new radionuclides
- Improved quantitative imaging and dosimetry
- Validated and quality-assured dosimetry workflows

“We are very proud to be one of the consortium members, together with diverse world-class partners, to propel forward this unique and ambitious Thera4Care project and driven precision healthcare,” concluded Marc Uszynski, CEO at DOSIsoft, *“We are convinced that dosimetry will play a crucial role in the future radiotheranostics solutions. The achievement of these missions is completely in line with the strategic development of DOSIsoft [PLANET® Dose](#) software - multi-radionuclide and personalized voxel-based dosimetry platform - to streamline and harmonize new radiotheranostics processes for optimized standard clinical practice.”*

To learn more about DOSIsoft [PLANET® Dose](#) -Theranostics solutions, visit DOSIsoft booth #S4 at the European Association of Nuclear Medicine (EANM) Congress in Hamburg, Germany (October 19th-23th, 2025).

About Thera4care

Thera4Care brings together partners from 14 European countries and the United States. The consortium's main academic partners include Università Cattolica del Sacro Cuore (UCSC) & Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Italy), Erasmus University (Netherlands), Jules Bordet Institute (Belgium), UniKlinik Essen (Germany), Gregorio Maranon General University Hospital (Spain) and Institut de Cancérologie de l'Ouest (France).

Thera4Care is funded by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101172788. The JU receives support from the European Union's Horizon Europe research and innovation programme and COCIR, EFPIA, EuropaBio, MedTech Europe, Vaccines Europe, Atley Solutions, Curasight, Dosisoft, Minerva Imaging, Perspective Therapeutics, and Tethera.

The grant agreement was signed on October 1, 2024, and runs through the next five years. For more information, please visit [the IHI website](#) or [Thera4Care project website](#).

About PLANET

PLANET® Onco Dose Edition 3 is developed by DOSIsoft SA in France. Version 3.1 is FDA 510(k) cleared for ⁹⁰Y Post-implantation and IIb class CE marked (MDD). The product or certain features may or may not be available for clinical use in any particular country.

About DOSIsoft

Founded in 2002, DOSIsoft designs, develops & delivers patient-specific imaging & dosimetry software solutions in Radiation Oncology & Nuclear Medicine to improve cancer patient safety & treatment quality. More than 20 years of innovation and R&D investments have led to world leading software used in over 600 hospital centers in 60 countries. Spin-off between Gustave Roussy and Institut Curie, DOSIsoft constantly innovates in partnership with the major cancer institutes and research centers in the world. www.dosisoft.com

Press contact Xiaolu CHEN | xiaolu.chen@dosisoft.com

DOSIsoft SA +33 (0)1 41 24 26 26 | 45/47, Avenue Carnot, 94230 Cachan – France

DOSIsoft Inc. +1 (844) 772-3674 | 2525 Ponce de Leon Ste 300, Coral Gables, FL 33134 – USA